Phased Reduction of Cyclosporine Combined with Mycophenolate Mofetil in Renal Transplant Recipients: Three-year Results of a Prospective Study
Journal of the Korean Surgical Society
; : 248-254, 2008.
Article
in Ko
| WPRIM
| ID: wpr-207334
Responsible library:
WPRO
ABSTRACT
PURPOSE: Although cyclosporine (CsA) improves short-term renal graft outcomes, many paradigms reduce or withdraw this drug because of its nephrotoxicity. However, inadequate immunosuppression with azathioprine led to little success. We conducted a prospective study to define the prolonged effect of CsA reduction in stable renal transplant recipients with mycophenolate mofetil (MMF). METHODS: Thirty-nine primary renal transplant recipients were divided into two cohorts, the AZA (N=13) and the MMF cohort (N=26). Both cohorts were allowed to reduce the CsA dose up to 50% of baseline within 3 to 4 months of conversion to AZA or MMF. Graft function, clinical parameters, and adverse events were monitored for up to 3 years. RESULTS: Ccr gradually deteriorated in the AZA cohort, but was stable in the MMF cohort. There was no episode of acute rejection or graft loss observed in either cohort. CONCLUSION: The CsA dose can be reduced in combination with MMF treatment in stable renal transplant recipients after 2 years of transplantation, resulting in beneficial effects on Ccr, lipid profiles, and blood pressure.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Rejection, Psychology
/
Azathioprine
/
Prospective Studies
/
Cohort Studies
/
Immunosuppression Therapy
/
Kidney Transplantation
/
Cyclosporine
/
Transplants
/
Mycophenolic Acid
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Language:
Ko
Journal:
Journal of the Korean Surgical Society
Year:
2008
Type:
Article